GB1107 / Damora Therapeutics - LARVOL DELTA

Effect of GB1107, a novel galectin-3 inhibitor on pro-fibrotic signalling in the liver. (PubMed, Eur J Pharmacol) - "GB1107 attenuated liver fibrosis and highlights Gal-3 as a therapeutic target for hepatic fibrosis."

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • LGALS3

Myocardin related transcription factor and galectin-3 drives lipid accumulation in human blood vessels. (PubMed, Vascul Pharmacol) - "Ex vivo organ culture of human arteries and veins can be used to evaluate lipid accumulation in the intact vascular wall, as well as adenoviral transduction and pharmacological inhibition. Although MRTF and galectin-3 may have beneficial, anti-inflammatory effects under certain circumstances, our results, which demonstrate a significant decrease in lipid accumulation, support further evaluation of MRTF- and galectin-3-inhibitors for therapeutic intervention against atherosclerotic vascular disease."

Journal • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders • LGALS3 • MRTFA

Discovery of Selective and Orally Available Galectin-1 Inhibitors. (PubMed, J Med Chem) - "High affinity and specificity were achieved by changing six-membered aryl-triazolyl substituents in a series of recently published galectin-3-selective α-d-thiogalactosides (e.g., GB1107 K galectin-1/3 3.7/0.037 μM) for five-membered heterocycles such as thiazoles...No cell cytotoxicity was observed for GB1490 up to 90 μM in the A549 cells. In pharmacokinetic studies in mice, GB1490 showed high oral bioavailability (F% > 99%)."

Journal • LGALS1